SCHEMBL2416787

SCHEMBL2416787

O=C(CCc1ccncc1)c1c(O)c2cccnc2n(-c2cccc([N+](=O)[O-])c2)c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 4/20 0.61
PDE4B Q07343 3/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
P2RX7 Q99572 2/20 0.37
MET P08581 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CTSB P07858 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413280 0.89 PDE4A (0.48) PDE4ALMNAALDH1A1MEN1KMT2A
SCHEMBL2412845 0.85 MAPT (0.45) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL2411173 0.85 FEN1 (0.46) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2409401 0.81 PDE4A (0.49) PDE4ALMNAALDH1A1MAPTMEN1
SCHEMBL2413828 0.80 PDE1A (0.49) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2415411 0.79 PDE4B (0.53) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL10660796 0.78 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL2416798 0.77 FEN1 (0.42) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL2411216 0.77 PDE1A (0.46) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL2408556 0.76 PTGDR2 (0.46) PDE4APDE4BPDE4CPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE4A 3/4885PDE4B 4/4885PDE4C 10/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE4A 3/4885PDE4B 6/4885PDE4C 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.